Premium
Preserving Flow in Liver Transplant Recipients: mTOR Inhibitors Everolimus and Sirolimus Are Not Peas From a Pod
Author(s) -
Bhat M.,
Charlton M.
Publication year - 2013
Publication title -
american journal of transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.89
H-Index - 188
eISSN - 1600-6143
pISSN - 1600-6135
DOI - 10.1111/ajt.12290
Subject(s) - everolimus , medicine , sirolimus , immunosuppression , liver transplantation , calcineurin , tacrolimus , transplantation , tolerability , pharmacology , urology , adverse effect
The results and implications of the pivotal phase III study of everolimus as primary immunosuppression following liver transplantation that led to FDA approval for everolimus in this setting are considered and discussed. See article by Saliba et al on page 1734.